OpenEvidence, the fastest-growing medical AI and clinical decision support platform in the U.S., announced a $210 million Series B funding round at a valuation of $3.5 billion. Google Ventures and Kleiner Perkins co-led the investment, with participation from Sequoia Capital, Coatue, Conviction, and Thrive. This funding brings OpenEvidence’s total raised capital to over $300 million.
The platform has seen exceptional growth, becoming the preferred AI-based medical search tool for more than 40% of U.S. physicians, used daily across more than 10,000 hospitals nationwide. The company now facilitates over 8.5 million clinical consultations monthly, representing growth exceeding 2,000% year-over-year.
Clinicians face increasing information overload, with the volume of medical research doubling every five years. Traditional medical databases are often fragmented and slow, forcing clinicians to spend excessive time away from patient care. OpenEvidence solves this by integrating content from strategic partnerships, including the American Medical Association and The New England Journal of Medicine, enabling clinicians to rapidly find relevant, evidence-based information at the point of care.
"When physicians' lives are hard, patients' lives are harder," said founder Daniel Nadler. "OpenEvidence’s commitment to building an AI copilot for clinicians is rooted in the belief that AI will be a force for good, ultimately benefiting healthcare professionals and patients."
OpenEvidence plans to use the new funding to further develop its advanced AI solutions, including the wide release of OpenEvidence DeepConsult™, a dedicated AI research agent designed specifically for physicians. DeepConsult autonomously analyzes hundreds of peer-reviewed medical studies, providing comprehensive, PhD-level research reports directly to clinicians, significantly reducing research time and enhancing decision-making capabilities.
The company will also use funds to expand its strategic content partnerships, aiming to increase its comprehensive medical knowledge library to support healthcare providers more effectively.
Founded by Daniel Nadler and Zachary Ziegler, OpenEvidence leverages AI to help clinicians make real-time, evidence-based medical decisions. The platform is notable for its rapid clinician adoption rate, outpacing all other medical technologies except Google itself. Nadler previously founded Kensho, an AI firm acquired by S&P Global in 2018 for $700 million.
In 2025, Nadler was recognized on TIME100 Health's list of the most influential figures in global health.
Investors recognize OpenEvidence’s potential to transform healthcare decision-making. "It's hard to imagine a better use for AI than OpenEvidence," stated John Doerr, chairman at Kleiner Perkins. Sangeen Zeb, General Partner at Google Ventures, emphasized, "Physicians are drowning in information but starving for timely insights. OpenEvidence changes that equation."
Mamoon Hamid, Managing Partner at Kleiner Perkins, noted the rare adoption level among physicians, adding, "OpenEvidence is setting a new global standard for evidence-based medical decisions."
